Drug development for depression medications now made easier
The rising costs of healthcare in the U.S. can pose an extra burden to patients suffering major depressive disorder.
The rising costs of healthcare in the U.S. can pose an extra burden to patients suffering major depressive disorder. However, they can save money if they buy Canadian Paxil or other medications to help them live a healthy, functional life. Clinical depression, obsessive compulsive disorder and other mental diseases are the product of abnormal activity by the neurotransmitter serotonin. Drugs such as Paxil interact with a protein known as the serotonin transporter (SERT), which helps regulate the actions of the neurotransmitter.
A recent study shows that the development process for drugs affecting SERT may now become easier.
Currently, scientists test the performance of novel medications in the lab by performing experiments to see how well they focus on and bind to their target cells and proteins. In these experiments, the new drug has to compete with control compounds that the scientists already know have affinity for the targets. These tests use radioactive substances to label the cells and proteins, and see how well the test drug works compared to the control compounds for the binding site.
Researchers from Germany figured out how to assess their novel medications through a technique known as mass spectrometry.
"This label-free technique provides all the advantages offered by classical binding studies, while avoiding the need to work with radioactive compounds," said Klaus Wanner, author of the study published in ChemMedChem. The study may lead to quicker drug development for a number of diseases.
|
